Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open RECLAIM-DCP: Long-Term Deutetrabenazine in Dyskinetic Cerebral Palsy
2019-001807-19Phase 3Active
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of deutetrabenazine in dyskinesia and dyskinetic cerebral palsy (DCP), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Primary safety endpoints. Started Oct 2019; status: active.
02
Drugs
deutetrabenazine
03
Conditions
dyskinesiadyskinetic cerebral palsy (DCP)
Beyond the preview
Go deeper on 2019-001807-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001807-19.